For Halloween, BioSpace collected six tales of thrills and chills from the pharma and biotech industries that will surely have you covering your eyes in terror.
What are key trends in the transparency compliance landscape? And, how are life sciences manufacturers tackling growing requirements
After multiple failures to develop therapeutics for Alzheimer’s disease, Biogen’s Michael D. Ehlers resigned from his role as head of research and development.
Trucode Gene Repair Inc. emerged from stealth mode with $34 million in financing to bolster the biotech startup’s triplex gene-editing technology.
Bristol-Myers Squibb has partnered with biotech accelerator BioMotiv. Bristol-Myers will become a limited partner of BioMotiv, investing in projects of mutual interest, with an option to buy the new companies that are funded and formed once there is a preclinical candidate.
Pfizer Inc. is investing $500 million to expand a manufacturing facility in Sanford, North Carolina, that plays a central role in the company’s efforts to become a major player in gene therapy.
Leading scientists, public policy experts and biotech industry leaders joined forces to launch “Working to Fight AMR,” a coalition working to raise public awareness of the growing threat posed by antimicrobial resistance.
German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics.
Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company
Clinical-stage biopharmaceutical company Gemphire Therapeutics Inc. and privately held clinical-stage biotechnology company NeuroBo Pharmaceuticals Inc. jointly announced a definitive agreement whereby NeuroBo will merge with a wholly owned subsidiary of Gemphire in an all-stock transaction.
Freenome snagged $160 million in Series B financing to support the development of the company’s early cancer detection blood test.